Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round
This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022.
Source: pr.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Mirror Effect. Real-time updates on events, politics, business and more.